Ontology highlight
ABSTRACT:
SUBMITTER: Yap TA
PROVIDER: S-EPMC7499606 | biostudies-literature | 2020 Sep
REPOSITORIES: biostudies-literature
Yap Timothy A TA O'Carrigan Brent B Penney Marina S MS Lim Joline S JS Brown Jessica S JS de Miguel Luken Maria J MJ Tunariu Nina N Perez-Lopez Raquel R Rodrigues Daniel Nava DN Riisnaes Ruth R Figueiredo Ines I Carreira Suzanne S Hare Brian B McDermott Katherine K Khalique Saira S Williamson Chris T CT Natrajan Rachael R Pettitt Stephen J SJ Lord Christopher J CJ Banerji Udai U Pollard John J Lopez Juanita J de Bono Johann S JS
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20200622 27
<h4>Purpose</h4>Preclinical studies demonstrated that ATR inhibition can exploit synthetic lethality (eg, in cancer cells with impaired compensatory DNA damage responses through ATM loss) as monotherapy and combined with DNA-damaging drugs such as carboplatin.<h4>Patients and methods</h4>This phase I trial assessed the ATR inhibitor M6620 (VX-970) as monotherapy (once or twice weekly) and combined with carboplatin (carboplatin on day 1 and M6620 on days 2 and 9 in 21-day cycles). Primary objecti ...[more]